

1 **FRONT MATTER**

2  
3 **Title**  
4  
5 **CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with**  
6 **Clinical Outcome**

7  
8 **Short Title**

9  
10 **CAR density influences CAR T cell efficacy**

11  
12  
13 **Authors**

14  
15 Paula Rodriguez-Marquez<sup>1,†</sup>, Maria E. Calleja-Cervantes<sup>1,2,†</sup>, Guillermo Serrano<sup>2,†</sup>, Aina Oliver-  
16 Caldes<sup>3</sup>, Maria L. Palacios-Berraquero<sup>4</sup>, Angel Martin-Mallo<sup>1</sup>, Cristina Calviño<sup>4</sup>, Marta Español-  
17 Rego<sup>5</sup>, Candela Ceballos<sup>6</sup>, Teresa Lozano<sup>7</sup>, Patxi San Martin-Uriz<sup>1</sup>, Amaia Vilas-Zornoza<sup>1,10</sup>,  
18 Saray Rodriguez-Diaz<sup>1</sup>, Rebeca Martinez-Turrillas<sup>1,10</sup>, Patricia Jauregui<sup>4</sup>, Diego Alignani<sup>8</sup>, Maria  
19 C. Viguria<sup>6</sup>, Margarita Redondo<sup>6</sup>, Mariona Pascal<sup>5</sup>, Manel Juan<sup>5</sup>, Alvaro Urbano-Ispizua<sup>3</sup>, Paula  
20 Rodriguez-Otero<sup>4</sup>, Ana Alfonso-Pierola<sup>4,10</sup>, Bruno Paiva<sup>1,8,10</sup>, Juan Jose Lasarte<sup>7</sup>, Susana  
21 Inoges<sup>4,9,10</sup>, Ascension Lopez-Diaz de Cerio<sup>4,9,10</sup>, Jesus San-Miguel<sup>1,4,10</sup>, Carlos Fernandez de  
22 Larrea<sup>3</sup>, Mikel Hernaez<sup>2,10,11,‡,\*</sup>, Juan R. Rodriguez-Madoz<sup>1,10,‡,\*</sup>, Felipe Prosper<sup>1,4,10,‡,\*</sup>

23  
24 **Affiliations**

25  
26 <sup>1</sup>Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.  
27 <sup>2</sup>Computational Biology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.  
28 <sup>3</sup>Department of Hematology. Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona.  
29 Barcelona, Spain  
30 <sup>4</sup>Hematology and Cell Therapy Department. Clínica Universidad de Navarra, CUN. Pamplona,  
31 Spain.  
32 <sup>5</sup>Department of Immunology. Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona.  
33 Barcelona, Spain.  
34 <sup>6</sup>Hematology Service. Hospital Universitario de Navarra. IdiSNA. Pamplona, Spain.  
35 <sup>7</sup>Immunology and Immunotherapy Program. Cima Universidad de Navarra. IdiSNA. Pamplona,  
36 Spain.  
37 <sup>8</sup>Flow Cytometry Core. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.  
38 <sup>9</sup>Immunology and Immunotherapy Department. Clínica Universidad de Navarra, CUN. Pamplona,  
39 Spain.  
40 <sup>10</sup>Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). Madrid, Spain.  
41 <sup>11</sup>Data Science and Artificial Intelligence Institute (DATAI). Universidad de Navarra. Pamplona,  
42 Spain.

43  
44  
45 \*Corresponding author. Email: [mhernaez@unav.es](mailto:mhernaez@unav.es); [jrodriguez@unav.es](mailto:jrodriguez@unav.es); [fprosper@unav.es](mailto:fprosper@unav.es)

46 †These authors contributed equally to this work

47 ‡These authors share senior authorship

48

49 **ABSTRACT**

50  
51 Identification of new markers associated with long-term efficacy in patients treated with CAR T  
52 cells is a current medical need, particularly in diseases such as multiple myeloma. In this study we  
53 address the impact of CAR density on the functionality of BCMA-CAR T cells. Functional and  
54 transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct  
55 show an increased tonic signaling with upregulation of exhaustion markers, increased *in vitro*  
56 cytotoxicity but a decrease in *in vivo* BM infiltration. Characterization of Gene Regulatory  
57 Networks using scRNA-seq identified regulons associated to activation and exhaustion upregulated  
58 in CAR<sup>High</sup> T cells, providing mechanistic insights behind differential functionality of these cells.  
59 Finally, we demonstrate that patients treated with CAR T cell products enriched in CAR<sup>High</sup> T cells  
60 show a significantly worse clinical response in several hematological malignancies. In summary,  
61 our work demonstrates that CAR density plays an important role in CAR T activity with significant  
62 impact on clinical response.

63

64 **Teaser**

65 High CAR molecule density affects CAR T cell activity and associates with impaired clinical  
66 response.

67

68

## 69 INTRODUCTION

70 Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising therapeutic tool  
71 against cancer, revolutionizing cancer immunotherapy (1). Second-generation CAR T cells have  
72 shown to induce impressive clinical responses in hematological malignancies, such as  
73 chemotherapy-resistant B cell leukemias and lymphomas (2–4) and multiple myeloma (MM) (5–  
74 7). Despite the high rates of remissions, not every patient achieves a complete response after CAR  
75 T-cell therapy. In addition, a significant number of patients experience a relapse of the disease.  
76 Particularly in patients with MM, despite their impressive responses, apparently, so far there is no  
77 a plateau in the survival curves after CAR T cell therapy (5–7), which contrast with results obtained  
78 with CD19 CAR T cells in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas  
79 (NHL).

80 It is well known that CAR T cells are heterogeneous products with multiple factors contributing to  
81 their efficacy. Several studies have demonstrated how extrinsic factors, like antigen density or  
82 tumor burden, strongly influence efficacy of CAR T cells (8, 9). In addition, factors related to CAR  
83 structure, like the costimulatory domain or the hinge length, can also affect the antitumoral  
84 potential of CAR T cells (10–12). Moreover, intrinsic cell factors, such as the differentiation state  
85 of T cells, the CD4/CD8 ratio or the T cell polyfunctionality have been correlated with the  
86 therapeutic efficacy and has led to the hypothesis that enrichment of CAR T cell products in T cells  
87 with a more immature phenotype may be associated with improvement in long term responses (13–  
88 16). On the other hand, an increase in T cells with an effector or exhausted phenotype may result  
89 in a reduced persistence of CAR T cells with a decrease in clinical response (13). Previous studies  
90 identified that CAR signaling in the absence of antigen stimulation, denominated tonic signaling,  
91 is associated to early T cell exhaustion (17–20), suggesting its role in triggering premature T-cell  
92 dysfunction. Additional factors related to the CAR construct may have an impact on functionality.  
93 For instance, recent studies have demonstrated that a more physiological expression of the CAR,  
94 by the integration of the transgene in the TRAC locus or the use of different promoters, can be  
95 associated with improved efficacy and reduced toxicity (21–23). These results also suggest that the  
96 density of CAR molecule in the membrane of CAR T cells might influence CAR signaling,  
97 affecting their antitumoral efficacy (23, 24). However, this hypothesis and the impact on clinical  
98 efficacy has not been formally explored.

99 Technological advances in genomics, such as single-cell sequencing, have allowed a notable  
100 progress towards understanding the genomic landscape of CAR T cells, providing some  
101 mechanistic insights into proper CAR T cell function (25–29). Moreover, functional commitment of  
102 CAR T cells is governed by complex Gene Regulatory Networks (GRN) that control CAR T cells  
103 at baseline as well as CAR T cell dynamics after antigen recognition being essential for CAR T  
104 functionality (30). Using scRNA-seq, recent studies have identified specific T cell signatures  
105 associated with efficacy and toxicity in patients with large B cell lymphomas (26), or molecular  
106 determinants of CAR T cell persistence such as *IRF7* mediated regulation of chronic interferon  
107 signaling (29), establishing this technology as a useful tool to improve efficacy of CAR T.

108 In this study, we address the impact of CAR density on the functionality of BCMA-CAR T cells.  
109 Phenotypic, functional, transcriptomic and epigenomic studies at bulk and single cell level revealed  
110 different profiles between CAR T cells with high and low expression of the CAR molecule  
111 (CAR<sup>High</sup> and CAR<sup>Low</sup> T cells). We show that CAR<sup>High</sup> T cells are associated with tonic signaling  
112 and an exhausted phenotype, and identify the molecular mechanisms involved in the different  
113 functionality of CAR<sup>High</sup> and CAR<sup>Low</sup> T cells. We define a molecular signature associated with  
114 increase CAR density that, when applied to CAR T cell products, may predict clinical response.  
115 These results would provide a useful tool to understand the mechanisms behind proper CAR T cell  
116 function and identify biomarkers of response with potential clinical implications.

117

## 118 RESULTS

### 119 CAR T cells exhibit a wide range of CAR density on cell surface that influences CAR- 120 mediated signaling

121 Current CAR T cell products are generated using retro/lentiviral vectors that render different levels  
122 of transduction and transgene expression within the cells, and consequently a wide range  
123 distribution in the number of CAR molecules in the surface of transduced cells. We hypothesized  
124 that this heterogeneity in CAR density could affect CAR-mediated signaling, and hence, influence  
125 the efficacy of CAR T cell products. To address this question, we first used a triple parameter  
126 reporter (TPR) system in Jurkat cells (31) to measure, by flow cytometry, CAR-mediated activation  
127 of the main signaling pathways (NFAT, NFkB and AP1) after tumor recognition using CAR T cells  
128 with different levels of CAR on the cell surface. Jurkat-TPR cells were infected with a second-  
129 generation CAR construct targeting BCMA, with 4-1BB as costimulatory domain, that was further  
130 modified to include a EGFRt reporter, facilitating the measurement of CAR level (Fig. S1). Then,  
131 subsets of Jurkat-TPR cells presenting different levels of CAR (termed CAR<sup>High</sup> and CAR<sup>Low</sup> cells)  
132 were selected according to the fluorescence intensity (FI) of EGFRt (top and bottom FI quartiles  
133 respectively, see methods), and analyzed after coculture with different BCMA-expressing MM cell  
134 lines (Fig. S1). We observed significantly increased levels of activation in the three mentioned  
135 pathways within the CAR<sup>High</sup> population. Moreover, a significant increase of activation of CAR<sup>High</sup>  
136 cells was also observed even in the absence of tumor cells, indicating an increase in tonic signaling  
137 at baseline (Fig. S1). We consistently observed this functional pattern with other CAR constructs  
138 targeting CD19, CD33 and HER2 (Fig. S1), indicating that a higher density of CAR molecules in  
139 the cell surface increases both the tonic signaling as well as the signal transduction after tumor  
140 encountering.

### 141 CAR density influences antitumoral response of CAR T cells targeting BCMA

142 To further analyze the effect of CAR density on antitumoral efficacy, we characterized CAR T  
143 cells from ten healthy donors that were generated using a BCMA-targeting CAR construct (derived  
144 from ARI-0002h) co-expressing BFP as reporter marker (Fig. S2). CAR T cells were sorted into  
145 CAR<sup>High</sup> and CAR<sup>Low</sup> subpopulations based on the expression of BFP (Fig. 1A and S3). CAR<sup>High</sup>  
146 T cells include those cells with a BFP FI > 1.2x10<sup>4</sup> (average FI 26861 ± 5795), while the CAR<sup>Low</sup>  
147 T cells subpopulation was restricted to BFP FI < 4x10<sup>3</sup> (average FI 2513 ± 388). These FI values  
148 corresponded to the top and bottom FI quartiles respectively (Fig. S3). Then, BFP FI values were  
149 used to quantify the number of CAR molecules on the surface of these two CAR T cell  
150 subpopulations using an antibody-binding capacity bead assay. CAR<sup>High</sup> T cells presented more  
151 than 5000 CAR molecules/cell, while the number of molecules/cell in CAR<sup>Low</sup> T cells was below  
152 1500 (Fig. S3). Vector copy number analysis revealed a significant higher number of viral  
153 integrations within CAR<sup>High</sup> T cells, with an average of 4.5 ± 1.3 integrations in CAR<sup>High</sup> T cells vs  
154 1.8 ± 0.3 in CAR<sup>Low</sup> T cells, and a significant increase in CAR mRNA expression levels was also  
155 observed, which could explain the increased CAR density observed in these cells (Fig. S3). We  
156 found increased cytotoxic activity and greater levels of IFN-γ, IL-2 and TNFα production in  
157 CAR<sup>High</sup> T cells (Fig. 1B-C). To determine the translational value of these findings, we examined  
158 CAR T cell levels in CAR T cell products from an academic clinical trial (CARTBCMA-HCB-01;  
159 NCT04309981) (Fig. S3). We observed an increased *in vitro* lytic activity in those CAR T cell  
160 products enriched in CAR<sup>High</sup> T cells (>30% of cells with >5000 CAR molecules/cell) (Fig. 1D).

161 Next, we analyzed the phenotype of CAR<sup>High</sup> and CAR<sup>Low</sup> T cells before and after stimulation with  
162 tumor cells (Fig. 1E and S4). At baseline, we observed a statistically significant enrichment of  
163 central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>) phenotypes within CAR<sup>High</sup> T cells, with  
164 concomitant reduction of naïve (T<sub>N</sub>) and stem central memory (T<sub>SCM</sub>) cells in both CD4<sup>+</sup> and CD8<sup>+</sup>  
165 subsets. After antigen stimulation, both populations acquired a T<sub>EM</sub>-T<sub>E</sub> phenotype, although

166 increased numbers of T<sub>E</sub> were observed in CAR<sup>High</sup> T cells (Fig. 1E and S4). These results suggest  
167 a higher degree of differentiation in CAR<sup>High</sup> T cells even in the absence of antigen stimulation.  
168 Moreover, we observed that CAR<sup>High</sup> T cells presented an increase in basal activation, with  
169 significant higher levels of HLA-DR<sup>+</sup> and CD137<sup>+</sup> cells, along with a higher percentage of CD8<sup>+</sup>  
170 T cells expressing a combination of two or more markers of exhaustion (LAG3, TIM3 and/or PD1)  
171 (Fig. 1F-H). These differences in cell exhaustion increased after antigen stimulation, with more  
172 than 30% of CD8<sup>+</sup> CAR<sup>High</sup> T cells expressing an exhausted phenotype (Fig. 1H).

173 To determine whether different CAR densities would affect long-term antitumor potential, we  
174 evaluated their efficacy *in vivo* using a stress test in NSG mice (21, 32). ARP-1 cells expressing  
175 luciferase (1x10<sup>6</sup> cells/animal) were transplanted in NSG mice and after 6 days 0.5x10<sup>6</sup> CAR<sup>High</sup> T  
176 or CAR<sup>Low</sup> T cells FACS-sorted from a BCMA-CAR T cells were infused into the animals (Fig.  
177 2A). Both subpopulations were able to eradicate tumor cells and increase survival of treated  
178 animals as demonstrated by luciferase measurements and by quantification of tumor cells into the  
179 bone marrow 28 days after treatment (Fig. 2B-E). However, when we analyzed the infiltration of  
180 CAR T cells in the bone marrow of the animals after 28 days, we observed a statistically significant  
181 reduction in the number of CAR T cells in animals treated with CAR<sup>High</sup> T cells in comparison with  
182 CAR<sup>Low</sup> T cells, suggesting a lower persistence of CAR<sup>High</sup> T (Fig. 2F). Overall, these results  
183 indicate that CAR<sup>High</sup> T cells show increased activation and tonic signaling and a more exhausted  
184 phenotype associated with an increase in *in vitro* cytotoxicity but a decrease in CAR T cell  
185 persistence in BM which could have an impact on the clinical response.

### 186 **CAR<sup>High</sup> T cells display different transcriptomic and chromatin landscape with increased** 187 **tonic signaling and T cell activation**

188 Given the differences observed in phenotype and persistence between CAR<sup>High</sup> T and CAR<sup>Low</sup> T  
189 cells, we delved into the transcriptomic and epigenetic landscape of the two subpopulations of CAR  
190 T cells. Sorted CD4<sup>+</sup> and CD8<sup>+</sup> CAR<sup>High</sup> and CAR<sup>Low</sup> T cell populations from six different CAR T  
191 cell productions were profiled using high-throughput RNA sequencing (RNA-seq) and assay for  
192 transposase-accessible chromatin (ATAC-seq). Transcriptomic analysis revealed less than 100  
193 genes differentially expressed (DEGs, FDR<0.05, Log<sub>2</sub>FC >2) between CAR<sup>High</sup> T and CAR<sup>Low</sup> T  
194 (Table S1). Similarly, the analysis of the ATAC-seq data revealed: i) a similar peak distribution in  
195 both populations, with >60% of the peaks located within the promoter regions and the first intron,  
196 and ii) a limited number of differential accessible regions identified between CAR<sup>High</sup> T and  
197 CAR<sup>Low</sup> T (Fig. S5 and Table S2). Interestingly, these small transcriptomic and epigenomic  
198 differences were enough to separate CAR<sup>High</sup> T cells from CAR<sup>Low</sup> T cells in a principal  
199 components analysis in both CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets (Fig. 3A and S6). Interestingly, DEG  
200 between CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells were associated to genes involved in tonic signaling and  
201 T cell activation (Fig. 3B and S6). These results corroborated our phenotypic observations (see  
202 previous sections), where CAR<sup>High</sup> T cells showed increased expression level of genes related to  
203 lymphocyte activation, such as HLA-DR or CD74, and costimulatory molecules, as TNFRSF4  
204 (OX40) and TNFRSF9 (4-1BB) (Fig. 3C and S6). Moreover, these results were consistent with the  
205 results observed in Jurkat-TPR experiments (see section above). While reduced overlapping was  
206 observed between DEGs and differential peaks, those genes showing differential expression and  
207 chromatin accessibility were mainly related to the activation and tonic signaling, including HLA-  
208 DRA, CIITA, TNFRSF9 and CTLA-4 (Fig. 3D and S6). Together, these results suggest that small  
209 differences in gene expression and chromatin accessibility associated to increased CAR levels can  
210 substantially modify the overall phenotypic and functional profile of CAR T cells.

### 211 **Single-cell sequencing reveals specific distribution of CAR<sup>High</sup> T cells**

212 To better understand the heterogeneity of CAR T cells and the influence of CAR level on their  
213 transcriptomic profile, we performed single cell transcriptomic analysis on 43,981 CAR T cells  
214 from three independent productions. After quality control and filtering, we performed an integrated



215 analysis and identified 23 clusters of CAR T cell subpopulations (Fig. S7). Clusters identified based  
216 on cell cycle gene signatures, those containing high levels of mitochondrial genes, as well as  
217 clusters lacking expression of T cell markers were excluded from further analysis (Fig. S7). Cell  
218 types and functional states of the remaining 15 clusters (containing 28,117 cells with range of  
219 7,416-10,5093 cells/donor) were defined according to the expression of previously described  
220 canonical markers (26–28) (Fig. 4A-B). Within CD4<sup>+</sup> cells we identified early memory (IL7R),  
221 memory (TCF7, CCR7, CD27), activated (HLA-DRA, OX40), cytotoxic (GZMA, PRF1) and Th2  
222 helper (GATA3) CAR T cells, with a minority of other subtypes including cells expressing genes  
223 related to glycolysis and IFN response. Among CD8<sup>+</sup> cells, we distinguished memory (TCF7,  
224 CCR7) and cytotoxic (GZMA, PRF1, NKG7) CAR T cells. Furthermore, in accordance with the  
225 phenotypical results, we identified a pre-exhausted cluster of CD8<sup>+</sup> CAR T cells characterized by  
226 the expression of cytotoxic genes along with inhibitory receptors, like LAG3 and TIGIT (33) (Fig.  
227 4B-C). Analysis of V(D)J rearrangement showed a polyclonal diversity of CAR T cells within all  
228 the clusters, indicating no specific enrichment of any particular clone (Table S3).

229 To robustly identify CAR T cells with high expression of the CAR construct in our single cell data,  
230 we developed gene signatures associated to both CD4<sup>+</sup> and CD8<sup>+</sup> CAR<sup>High</sup> T cells, using DEGs  
231 from bulk RNA-seq analysis between CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells (Table S4), as these  
232 populations were sorted based on CAR protein expression (see methods). We found a better  
233 correlation between the gene signature and CAR protein level, than the one observed between the  
234 expression of the CAR gene and its protein expression (Fig. S8). Moreover, the possibility to  
235 extrapolate these gene signatures to other datasets was assessed via leave-one-out cross-validation  
236 (Fig. S8). Then, we annotated CAR<sup>High</sup> T cells in our single cell data using the developed signatures  
237 (Fig. 5A), and we observed that CAR<sup>High</sup> T cells mainly localized within activated CD4<sup>+</sup> cells,  
238 representing more than 50% of the cells in cluster 6 and almost 80% of the cells in cluster 17 (Fig.  
239 5B). Furthermore, in the CD8<sup>+</sup> T cell compartment, CAR<sup>High</sup> T cells were more represented in  
240 cluster 9 showing a pre-exhausted phenotype (Fig. 5B). These results are in accordance with our  
241 previous phenotypic and transcriptomic analysis performed in sorted CAR<sup>High</sup> T and CAR<sup>Low</sup> T cell  
242 populations, where CAR<sup>High</sup> T cells were significantly enriched in activation and tonic signaling  
243 signatures (Fig. 5C-D). Moreover, we perform this analysis using an independent single cell public  
244 dataset of CAR T products targeting CD19 from patients with DLBCL (26), obtaining similar  
245 results (Fig. S9). Altogether, our results would indicate a strong association between tonic  
246 signaling, CAR T cell activation and cell exhaustion that is increased in CAR T cells with high  
247 CAR density defined either by the gene signature or the protein expression.

## 248 **CAR density is associated with differential activation of regulatory networks**

249 To elucidate the molecular regulation of CAR<sup>High</sup> T cells we applied SimiC (34), a novel GRN  
250 inference algorithm for scRNA-seq data that imposes a similarity constraint when jointly inferring  
251 the GRNs for each specific cell state. Based on this analysis, we observed regulons (a TF and its  
252 associated target genes) that were similarly activated between CAR<sup>High</sup> and the rest of the CAR T  
253 cells (Fig. S10), such as regulons implicated in T cell differentiation (GATA3, RUNX3) and signal  
254 transduction (STAT1, REL, RELA, JUN/AP1) (35–37). On the other hand, we identified some  
255 regulons that were more active in CAR<sup>High</sup> T cells, like STAT3, a TF associated with development  
256 and maintenance of T cell memory (38), or ARID5A, a TF related to the control of the stability of  
257 STAT3 (39) (Fig. S10) and other regulons that presented reduced activity in CAR<sup>High</sup> T cells, like  
258 BTG2, a TF related to the prevention of proliferation exacerbation and spontaneous activation (40)  
259 (Fig. S10). These changes in regulon activity could explain the increased central memory  
260 phenotype and also provide a regulatory mechanism for the increased activation observed in  
261 CAR<sup>High</sup> T cells.

262 Interestingly, we also observed regulons presenting a multimodal activation profile. To determine  
263 whether this distribution might be related to different activity between clusters, we computed the

264 distribution of the regulon activity in each cluster (provided it contain at least 5% of CAR<sup>High</sup> T  
265 cells) (Fig. S10). As an example, we observed that the activity of RFX5 regulon, a member of the  
266 RFX family that interacts with HLA class II genes and promotes their transcription (41, 42), was  
267 overexpressed in CD8<sup>+</sup> CAR<sup>High</sup> T cells, independently of the T cell subtype. However, RFX5  
268 regulon activity progressively increased through CD8<sup>+</sup> differentiation when we analyzed CD8<sup>+</sup>  
269 CAR T cells that were not CAR<sup>High</sup> T, from memory, to cytotoxic and finally to pre-exhausted cells  
270 (Fig. 6A). In addition, we searched for regulons that could explain the exhausted phenotype  
271 observed in CAR<sup>High</sup> T cells. We observed that NR4A1 and MAF regulons, already described as  
272 drivers of T cell exhaustion (43–45), were more active in CAR<sup>High</sup> T cells (Fig. 6A). On the other  
273 hand, the SATB1 regulon, related to PD1 inhibition (46), presented lower activity in CAR<sup>High</sup> T  
274 cells (Fig. 6A). All these results may provide molecular mechanism underpinning the exhausted  
275 phenotype observed in CAR<sup>High</sup> T. Overall, our GRN analysis using SimiC provides mechanistic  
276 insights into the regulatory networks behind the phenotypic and functional differences observed in  
277 CAR<sup>High</sup> T cells, identifying regulons that regulate T cell function previously described, supporting  
278 the usefulness of this methodology. More importantly, the use of SimiC permits the generation of  
279 novel hypothesis based on identified regulatory factors that could be modulated, ultimately to the  
280 design of optimized CAR T therapies.

### 281 **CAR<sup>High</sup> T gene signature is associated with clinical response**

282 Given the differences in functionality between CAR<sup>High</sup> and CAR<sup>Low</sup> T cells, we reasoned that CAR  
283 density might have an impact on the clinical response to CAR T-cell therapies. To evaluate this  
284 hypothesis, we applied the gene signatures associated with CAR<sup>High</sup> T cells to infusion products  
285 from several clinical trials with public transcriptomic data available (25, 26). We first applied our  
286 CD4<sup>+</sup> and CD8<sup>+</sup> signatures to bulk RNA-seq data of 34 infusion products from adult CLL patients  
287 treated with CTL019 (25). We observed that products from patients with poor clinical response  
288 (partial responders and non-responders) presented a significant higher score of both CD4<sup>+</sup> and  
289 CD8<sup>+</sup> CAR<sup>High</sup> T signatures (Fig. 7A). We also assessed CAR<sup>High</sup> T signature on a single cell RNA-  
290 seq dataset comprising anti-CD19 CAR T infusion products from 24 patients with DLBCL (26).  
291 We found that the products from non-responder patients were significantly enriched in CD8<sup>+</sup>  
292 CAR<sup>High</sup> T cells (Fig. 7B), supporting the correlation between CAR density and clinical response.  
293 Finally, we examined the correlation between the clinical response and the expression of CAR  
294 measured by FACS, in the cell products of an academic clinical trial assessing ARI-0002h, a CAR  
295 T cell targeting BCMA (CARTBCMA-HCB-01; NCT04309981). Patients with partial response  
296 (less or equal than VGPR) showed an increase in the number of CAR<sup>High</sup> T within the infusion  
297 product versus the patients presenting sCR (Fig. 7C). Moreover, a shorter duration of response was  
298 observed in patients with increased percentage of CAR<sup>High</sup> T cells (p=0.04, as continuous variable  
299 in Cox regression model). No statistical correlation was observed with the development or grade  
300 of cytokine release syndrome (CRS), although the patients of this cohort presented only low-grade  
301 CRS (grades 1 and 2). Overall, our data suggest that CAR T therapeutic products enriched in T  
302 cells with high CAR density on the membrane, would impact negatively on the clinical response.

303

## 304 DISCUSSION

305 The functionality of CAR T cells relies on the interaction between the tumor and engineered T cells  
306 (*I*). However, as living drugs, CAR T cells are heterogeneous products in which intrinsic and  
307 extrinsic factors can influence their functionality having a significant impact on their clinical  
308 efficacy (8–16). Among others, the level of antigen expression has been associated with anti-tumor  
309 response (8, 24). Our study contributes to identify new determinants of CAR T cell function  
310 demonstrating a clear role of the level of CAR expression on the functionality of CAR T cells. Our  
311 results indicate that high levels of CAR expression are associated with increased tonic signaling  
312 and a cell exhausted phenotype, characterized by the expression of multiple inhibitory receptors,  
313 such as PD1, CTLA4, LAG3, TIM3 and TIGIT, among others. This phenotype has been associated  
314 to reduced responses and worse long-term relapse free survival (13, 25, 48), which is consistent  
315 with our findings demonstrating decreased responses in patients with increased levels of CAR<sup>High</sup>  
316 T cells in different hematological malignancies.

317 Previous studies have demonstrated that constitutive signaling induced by multiple factors related  
318 to the different CAR moieties (49, 50), are associated to early T cell exhaustion (17–20). For  
319 instance, a recent study has shown fundamental differences in CAR signaling between CAR T cells  
320 with CD28 or CD8 transmembrane domains (TMD) related to the heterodimerization potential of  
321 the different transmembrane domains (51). Our results indicated that an increased density of the  
322 CAR molecule in the surface of the T cells (CAR<sup>High</sup> T cells), triggered by a higher number of viral  
323 integrations, could be enough to induce spontaneous clustering of the chimeric receptor molecules  
324 leading to tonic signaling. Interestingly, tonic signaling was not restricted to CAR<sup>High</sup> T cells  
325 targeting BCMA, since it was also observed in CAR<sup>High</sup> T cells with different specificities (CD19,  
326 CD33 and HER2), suggesting that this phenomenon was related to CAR density rather than CAR  
327 specificity.

328 Most CAR T constructs are generated using retro/lentiviral vectors with strong promoters, like  
329 human EF1a or the murine stem cell virus LTR (MSCV), with no physiological regulation. These  
330 promoters induce high levels of CAR expression that can lead to tonic signaling and premature  
331 exhaustion. The possibility of reducing gene expression via weaker promoters as well as through  
332 more physiological promoters has been associated with decreased tonic signaling (22, 23, 52). In  
333 fact, the use of the MND promoter has been shown to reduce CAR surface density, while EF1a  
334 promoter increased its density, leading to a higher cytotoxic activity, cytokine production and  
335 expression of exhaustion markers (23). Thus, the use of physiological promoters would be a  
336 strategy to prevent an increase in CAR<sup>High</sup> T cells, thus limiting exhaustion of CAR-T and favoring  
337 long term persistence and antitumor efficacy (22).

338 The increased tonic signal and the concomitant basal activation of CAR<sup>High</sup> T cells resulted in an  
339 increase in tumor cytotoxicity *in vitro*. The higher cytotoxicity and cytokine production observed  
340 in CAR<sup>High</sup> T cells is also consistent with previous reports describing differences in antitumoral  
341 efficacy due to increased ligand-independent signaling (32, 53). Nevertheless, the pre-exhausted  
342 phenotype of CAR<sup>High</sup> T cells could compromise their long-term persistence and function. Our  
343 results from the *in vivo* experiments based on “stress tests” (32, 54) support this hypothesis, since  
344 we observed reduced bone marrow infiltration of CAR<sup>High</sup> T cells. However, the use of CAR<sup>Low</sup> T  
345 cells was not associated with improved survival of the animals since both CAR T populations were  
346 able to induce strong antitumor responses. Unfortunately, the use of immunodeficient mouse  
347 models is a significant limitation for testing CAR T cell efficacy, as well as toxicity. The use of  
348 humanized mice, or syngeneic mouse models together with mouse CAR T cells, should help to  
349 better characterize *in vivo* the impact of CAR expression of long-term efficacy of the different  
350 products. Nevertheless, the clinical correlation between response and decrease number of CAR<sup>High</sup>  
351 T cells in the infusion product would also be consistent with the hypothesis that infusion of CAR<sup>High</sup>  
352 T cells could compromise their long-term persistence and function.



353 The avidity of the scFv against the antigen plays an important role on the functionality of the CAR  
354 T cells and its control may result in more effective therapies (55, 56). Moreover, strategies  
355 combining the avidity of scFvs and the targeting of two molecules (or epitopes) may represent  
356 interesting approaches to increase the antitumoral efficacy and to reduce the toxicity (57, 58). This  
357 would be particularly relevant for MM where, despite impressive initial responses, a significant  
358 number of patients experience a relapse after CAR T cell therapies (5, 6). However, the impact that  
359 CAR density could play on these approaches using CAR T cells with strong avidity and/or targeting  
360 several molecules, would be an additional aspect that should be further analyzed.

361 A relevant question faced in this work was the development of specific methodology for proper  
362 identification of CAR<sup>High</sup> T cells from transcriptomic data. We defined a molecular signature  
363 associated with increased CAR density, for both CD4<sup>+</sup> and CD8<sup>+</sup> CAR T cells, that showed a higher  
364 correlation with cell surface CAR levels than the RNA expression. The implications of these  
365 signatures were severalfold: 1) this signature was key to annotate cells and identify clusters  
366 enriched in CAR<sup>High</sup> T cells; 2) in addition, these signatures allowed us to perform GRN analysis  
367 using single cell data and identify key regulons associated to exhaustion of CAR T cells, such as  
368 NR4A1 and MAF (43–45), that were differentially activated in CAR<sup>High</sup> T cells, providing  
369 mechanistic insights of the regulatory pathways driving the differences between CAR T cells with  
370 different CAR density; 3) finally, the definition of the signature associated with CAR<sup>High</sup> T cells  
371 allowed us to apply the gene signature to transcriptomic data from CAR T cell products of patients  
372 undergoing CAR T treatment (25, 26), demonstrating a correlation between CAR expression and  
373 response in several cohorts of patients with different diseases (CLL and DLBCL). In the case of  
374 MM patients undergoing CAR T therapies, we also found a correlation between the CAR levels  
375 present on the therapeutic products and both the depth of response and its duration. These  
376 observations support our hypothesis that the presence of a high number of CAR<sup>High</sup> T cells within  
377 the products limits the efficacy of CAR T therapies and suggests that the application of our gene  
378 signature may represent a new prognostic factor in patients treated with CAR T cells.

379 In summary, our data demonstrate that CAR density plays an important role in CAR T activity with  
380 an impact on clinical response. Moreover, the comprehension of regulatory mechanisms driven by  
381 CAR densities at the single cell level offers an important tool for the identification of key regulatory  
382 factors, that could be modulated for the development of improved therapies. Lastly, the application  
383 of a gene signature associated to increased CAR density, if validated in additional cohorts may  
384 represent a valuable tool for predicting responses in patients undergoing CAR T cell therapy.

385

## 386 MATERIALS AND METHODS

### 387 Cell lines

388 Jurkat-TPR (kindly provided by Dr. P. Steinberg; Medical University of Vienna), ARP-1-GFPLuc  
389 (kindly provided by Dr. Epstein; University of Arkansas for Medical Sciences), U266, MOLP8,  
390 K562 and K562-CD19 cells were cultured in RPMI 1640 supplemented with 10% FBS. MOLM13  
391 and MV411 were cultured in RPMI 1640 supplemented with 20% FBS. HEK293T and BT474 cells  
392 were cultured in DMEM supplemented with 10% FBS. All media were supplemented with 1%  
393 penicillin/streptomycin and 1% L-Glutamine. All cell lines were maintained at 37°C in 5% CO<sub>2</sub>.

### 394 Lentiviral vector construction and virus preparation

395 A third-generation self-inactivating lentiviral vector (pCCL) was used to express under the EF1a  
396 promoter a second-generation CAR constructs targeting BCMA (J22.9 clone from ARI-0002h),  
397 CD19 (FMC63 clone), CD33 (my96 clone) or HER2 (FRP5 clone). CAR structure comprised the  
398 single-chain variable fragment (scFv), a CD8 hinge and transmembrane domain, the 4-1BB and  
399 CD3 $\zeta$  endodomains fused to a truncated version of the EGFR or a BFP reporter gene. Lentiviral  
400 vectors were produced in HEK293T cells following standard procedures. Briefly, 6 $\times$ 10<sup>6</sup> cells were  
401 co-transfected with LV vector along with pMDLg/pRRE (Gag/Pol), pRSVRev and pMD2.G  
402 (VSVG envelope) packaging plasmid using Lipofectamine 2000 (Invitrogen). Supernatants were  
403 collected 40h after transfection, filtered, concentrated using Lenti-X Concentrator (Takara)  
404 following manufacturer specifications and stored at -80°C until use.

### 405 Analysis of CAR signaling in Jurkat-TPR

406 Jurkat-TPR cells, transduced at MOI of 1 with CARs targeting BCMA, CD33, CD19 or HER2,  
407 were co-cultured in triplicate with ARP1-GFPLuc, MOLP8 and U266 cells for BCMA CARs,  
408 MOLM13 and MV4-11 cells for CD33, K562-CD19 cells for CD19 CARs or BT474 cells for  
409 HER2 CARs, at a 1:1 effector to tumor cell ratio. Non-transduced Jurkat-TPR cells were used as  
410 control. CAR<sup>High</sup> and CAR<sup>Low</sup> subpopulations were defined according to the fluorescence intensity  
411 (FI) using an EGFR-APC antibody (clone AY13, Biolegend). Thresholds for CAR<sup>High</sup> and CAR<sup>Low</sup>  
412 were define as the top and bottom FI quartiles respectively (CAR<sup>High</sup>: FI > 1.5 $\times$ 10<sup>5</sup> and CAR<sup>Low</sup>:  
413 FI < 2 $\times$ 10<sup>4</sup>). Activation of the NFAT, NF- $\kappa$ B and AP-1 pathways was quantified before and 24h  
414 after co-culture with tumor cells measuring eGFP, eCFP and mCherry emissions respectively,  
415 using a CytoFLEX LX Flow Cytometer (Beckman Coulter) (Fig. S1).

### 416 CAR T cell generation

417 CD4<sup>+</sup> and CD8<sup>+</sup> cells were isolated from PBMCs using CD4 and CD8 MicroBeads (Miltenyi  
418 Biotec) in the AutoMACS Pro Separator (Miltenyi Biotec). Isolated T cells were activated with 10  
419  $\mu$ l/ml T cell TransAct (Miltenyi Biotec) for 48h and infected with the CAR lentiviral vector at MOI  
420 2 with 10  $\mu$ l/ml of LentiBoost (Sirion Biotech). CAR T cells were expanded in RPMI 1640 culture  
421 medium supplemented with 3% human serum (Sigma), 1% penicillin/streptomycin and 625 IU/ml  
422 of human IL-7 and 85 IU/ml of human IL-15 (Miltenyi Biotec). CAR T cells were counted, and  
423 the concentration was adjusted to 1 $\times$ 10<sup>6</sup> cells/ml every two days.

### 424 Flow cytometry and CAR<sup>High</sup> and CAR<sup>Low</sup> T cell isolation

425 Phenotypic characterization of T cells and CAR T cells was performed at day 0 and 13 of the  
426 production, respectively. All antibodies were purchased from Biolegend unless otherwise stated  
427 (Table S5). Data was acquired on a BD FACSCanto II (BD Biosciences) and analyzed using the  
428 FlowJo Software version 10 (Tree Star). CAR<sup>High</sup> and CAR<sup>Low</sup> T cell subpopulations were sorted  
429 according to the BFP FI. Thresholds for CAR<sup>High</sup> and CAR<sup>Low</sup> were define as the top and bottom  
430 FI quartiles respectively (CAR<sup>High</sup>: FI > 1.2 $\times$ 10<sup>4</sup>; CAR<sup>Low</sup>: FI < 4 $\times$ 10<sup>3</sup>) (Fig. S3). All cells were  
431 sorted using a MoFlo Astrios EQ (Beckman Coulter).

432

### 433 **Quantification of CAR density**

434 The number of CAR molecules on the surface of CAR T cell products from healthy donors and  
435 MM patients was quantitated using Quantum Simply Cellular (QSC) (Bangs Laboratories, USA:  
436 815), according to the manufacturer's protocol. This methodology allows the conversion of  
437 fluorescence intensity value into absolute numbers of binding molecules using a calibration curve.  
438 Data acquisition was performed on a BD FACSCanto II (BD Biosciences), and the results were  
439 analyzed using FlowJo Software version 10 (Tree Star). A threshold of 5000 and 1500 molecules  
440 was applied to define cells as CAR<sup>High</sup> or CAR<sup>Low</sup> respectively, since these were a lower bound  
441 (5000 on CAR<sup>High</sup>) and an upper bound (1500 on CAR<sup>Low</sup>) on number of molecules present on the  
442 samples sorted for functional and transcriptomic experiments.

### 443 **Viral copy number**

444 Viral copy number (VCN) per cell were determined by qPCR. Genomic DNA was extracted using  
445 the DNeasy Blood and Tissue Kit (Qiagen). VCN/cell were quantified by duplex detection of the  
446 Psi sequence, normalized to ALBUMIN, using specific primers and detected with the TaqMan  
447 probes (Table S6). qPCR was performed using the Absolute qPCR Mix Low ROX Mix (Thermo  
448 Scientific) in a QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific). Results were  
449 analyzed in QuantStudio 3 Design and Analysis Software (Thermo Fisher Scientific).

### 450 **Cytotoxicity assay and cytokine production**

451 Cytotoxicity was determined using ARP1-GFP<sup>Luc</sup> as target tumor cells. Briefly, ARP1-GFP<sup>Luc</sup>  
452 cells were cultured with CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells at different ratios in RPMI 1640 culture  
453 medium, supplemented with 3% human serum (Sigma) and 1% penicillin/streptomycin in Nunc™  
454 96-Well Round Bottom plates (ThermoFisher Scientific). After 24h, luminescence measured using  
455 the Bright-Glo™ Luciferase Assay System (Promega) according to the manufacturer's  
456 instructions. IFN $\gamma$ , TNF $\alpha$  and IL-2 cytokine production was quantified using BD™ Immunoassay  
457 ELISA reagents (BD Biosciences) following manufacturer protocol.

### 458 ***In vivo* experiments**

459 All experimental procedures were approved by the Ethics Committee of the University of Navarra  
460 and the Institute of Public Health of Navarra according to European Council Guidelines. NOD-  
461 SCID-Il2rg<sup>-/-</sup> (NSG) mice were purchased from The Jackson Laboratory (JAX) and bred and  
462 maintained in-house in a pathogen-free facility. Eight-to-twelve-week-old male or female mice  
463 were irradiated at 1.5 Gy at day -1 and  $1 \times 10^6$  ARP1-GFP<sup>Luc</sup> cells were intravenously injected  
464 the following day. Mice were randomized to ensure equal pre-treatment tumor burden before CAR  
465 T cell treatment. At day 6 mice received i.v. injection of  $0.5 \times 10^6$  either CAR<sup>High</sup> T or CAR<sup>Low</sup> T  
466 cells. A subset of mice was sacrificed at day 28 to analyze the presence of cells in bone marrow.  
467 Tumor progression was measured by bioluminescent imaging using the PhotonIMAGER  
468 (Biospacelab). Signal was quantified using M3Vision Analysis Software (Biospacelab). Mice were  
469 humanely euthanized when mice demonstrated signs of morbidity and/or hindlimb paralysis.

### 470 **RNA-sequencing and bioinformatics analysis**

471 RNA-seq was performed following MARS-seq protocol adapted for bulk RNA-seq (59, 60) with  
472 minor modifications. RNA-seq libraries quantification was done with Qubit 3.0 Fluorometer (Life  
473 Technologies) and size profiles were examined using Agilent's 4200 TapeStation System.  
474 Libraries were sequenced in an Illumina NextSeq500 at a sequence depth of 10 million reads per  
475 sample. Samples were aligned to the Human genome (GRCh38) with STAR (v2.6.1). Gene  
476 expression was quantified with quant3p (github.com/ctlab/quant3p). Downstream analyses were  
477 performed in R (v3.6.2). Data transformation, normalization, and differential gene expression

478 analysis were performed with DESeq2. T cell activation and tonic signaling gene signatures used  
479 in this work were obtained from previous publications (25–28) (Table S7).

#### 480 **Assay for transposase-accessible chromatin (ATAC-seq) and bioinformatics analysis**

481 Accessible chromatin mapping was performed using FAST-ATAC-seq (61) with minor  
482 modifications. Libraries were quantified and their size profiles examined as described above.  
483 Sequencing was carried out in an Illumina NextSeq500 at a depth of 20 million reads per sample.  
484 ATAC-seq reads were aligned to the human genome (GRCh38) using Bowtie2 (v2.3.4). Peak  
485 calling from each individual replicate was performed with MACS2 (v.2.1.0). Differential  
486 accessible analysis was analyzed with Cseq R package. The consensus peak set was derived from  
487 the union of all replicate peak sets for both conditions. For normalization, a non-linear LOESS-  
488 based (LOESS: Locally estimated scatterplot smoothing) method was applied. Differential  
489 enrichment was analyzed using edgeR package. Finally, ChIPseeker R package was used for  
490 annotation and visualization of genomics features.

#### 491 **Single cell RNA-sequencing (scRNA-seq)**

492 scRNA-seq was performed in FACS-sorted CAR T cells (BFP<sup>+</sup> cells) from three independent  
493 donors using the Chromium Single Cell 5' Reagent Kit (10X Genomics) according to the  
494 manufacturer's instructions. After quality control and quantification, single cell libraries were  
495 sequenced at an average depth of at least 30000 reads/cell. 43,981 cells were analyzed, and 28,117  
496 cells passed quality control with an average sequencing depth of 42,296 reads/cell, yielding an  
497 average of 2,541 genes/cell. TCR  $\alpha/\beta$  sequencing was performed with 10X Genomics Single Cell  
498 V(D)J Immune Profiling Solution (10 $\times$  Genomics). After quality control and quantification, single  
499 cell V(D)J enriched libraries were pooled and sequenced at a minimum depth of 5000 reads per  
500 cell.

501 scRNA-seq data were demultiplexed, aligned to the human reference (GRCh38) and the feature-  
502 barcode matrix was quantified using Cell Ranger (v6.0.1) from 10X Genomics. Further  
503 computational analysis was performed using Seurat (v3.1.5). Cells were subjected to QC filters  
504 based on the number of detected genes, number of UMIs and proportion of UMIs mapped to  
505 mitochondrial and ribosomal genes per cell. Each dataset was subjected to normalization,  
506 identification of highly variable genes and removal of unwanted sources of variation. Integration  
507 of all the dataset was based on Seurat's canonical correlation analysis. Unsupervised clustering  
508 analysis with the resolution set to 0.8 yield a total of 23 cell clusters. Non-linear dimensional  
509 reduction was performed using t-distributed stochastic neighbor embedding (t-SNE) and UMAP.  
510 To describe the cell types and states defined by each cluster, we performed a manual review of the  
511 differentially expressed genes that were identified for each cell cluster by Seurat, using canonical  
512 marker genes as reference. TCR reconstruction and paired TCR clonotype analysis was performed  
513 using Cell Ranger v6.0.2 for V(D)J sequence assembly.

#### 514 **Generation of CAR<sup>High</sup> signature**

515 The CAR<sup>High</sup> signature was generated using differentially expressed genes between CAR<sup>High</sup> T and  
516 CAR<sup>Low</sup> T cell samples for each cell type (CD4<sup>+</sup> and CD8<sup>+</sup> cells). Specifically, the signature is  
517 created as:

$$518 \quad S = \sum_i \log(F_i) * z(\log(E_i + 0.5))$$

519 where  $F_i$  is the fold change of the gene  $i$  between the CAR<sup>High</sup> T and CAR<sup>Low</sup> T samples,  $z(\cdot)$  is the  
520 function computing the z-score and  $E_i$  is the normalized gene expression for the  $i$ -th gene. This  
521 signature takes the z-score of the logarithm of the expression gene, allowing to compare the genes



522 between them, and multiplying it by the logarithm of the fold-change to imprint the directionality  
523 of the signature gene.

524

### 525 **Gene regulatory network analysis**

526 Cells were labelled as CAR<sup>High</sup> by applying the developed CAR<sup>High</sup> signature. Then, using the most  
527 variable 300 TFs and 3000 genes, SimiC was run with the default parameters across CAR<sup>High</sup>-  
528 labelled cells and the rest. GRNs were plotted using the GRN incidence matrices provided by  
529 SimiC. The histograms for the different regulons were computed from the ‘Regulon Activity Score’  
530 provided by SimiC. This score was also used to compute the regulatory dissimilarity score for the  
531 selected cell clusters.

### 532 **Patient samples and clinical data**

533 Samples were obtained from patients with MM enrolled in the academic clinical trial  
534 CARTBCMA-HCB-01 (NCT04309981), lead by Dr. Fernandez de Larrea (Hospital Clínic in  
535 Barcelona), assessing the BCMA-CAR T ARI-0002h, developed at IDIBAPS/Hospital Clínic in  
536 Barcelona. All subjects provided written informed consent. Clinical response was defined  
537 according to the MM Response Criteria (62) as: Stringent Complete Response (sCR), Very Good  
538 Partial Response (VGPR), Partial Response (PR) and Progressive Disease (PD). The CAR<sup>High</sup>  
539 signature was applied to gene expression data publicly available (25, 26), which allowed us to: i)  
540 quantify the number of CAR<sup>High</sup> T cells within CD4<sup>+</sup> and CD8<sup>+</sup> population in CAR T cell products  
541 when scRNA-seq data was available; and ii) to score the CAR T cell products according to CD4<sup>+</sup>  
542 and CD8<sup>+</sup> CAR<sup>High</sup> signature when bulk RNA-seq data was available. The clinical data was judged  
543 the same way as in the original manuscript, grouping the different treatment responses into: Non  
544 Response (NR), Partial Response (PR), Partial Response with Transformed Disease (PRTD) and  
545 Complete Response (CR).

### 546 **Statistical Analysis**

547 Statistical analyses were performed using GraphPad Prism for Mac version 9.3.1. The different  
548 tests used in this work are indicated in the figure legend.

549

## 550 References

- 551
- 552 1. C. H. June, M. Sadelain, Chimeric antigen receptor therapy. *New England Journal of Medicine*. **379** (2018),
- 553 pp. 64–73.
- 554 2. S. J. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. Jäger, S. Jaglowski,
- 555 C. Andreadis, J. R. Westin, I. Fleury, V. Bachanova, S. R. Foley, P. J. Ho, S. Mielke, J. M. Magenau, H.
- 556 Holte, S. Pantano, L. B. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. T. Maziarz, Tisagenlecleucel in
- 557 adult relapsed or refractory diffuse large B-cell lymphoma. *New England Journal of Medicine*. **380**, 45–56
- 558 (2019).
- 559 3. S. L. Maude, T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E.
- 560 Stefanski, G. D. Myers, M. Qayed, B. de Moerloose, H. Hiramatsu, K. Schlis, K. L. Davis, P. L. Martin, E.
- 561 R. Nemecek, G. A. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. H.
- 562 June, B. L. Levine, P. Wood, T. Taran, M. Leung, K. T. Mueller, Y. Zhang, K. Sen, D. Leibold, M. A.
- 563 Pulsipher, S. A. Grupp, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.
- 564 *New England Journal of Medicine*. **378**, 439–448 (2018).
- 565 4. S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos, C. A. Jacobson, I. Braunschweig, O.
- 566 O. Oluwole, T. Siddiqi, Y. Lin, J. M. Timmerman, P. J. Stiff, J. W. Friedberg, I. W. Flinn, A. Goy, B. T.
- 567 Hill, M. R. Smith, A. Deol, U. Farooq, P. McSweeney, J. Munoz, I. Avivi, J. E. Castro, J. R. Westin, J. C.
- 568 Chavez, A. Ghobadi, K. v. Komanduri, R. Levy, E. D. Jacobsen, T. E. Witzig, P. Reagan, A. Bot, J. Rossi, L.
- 569 Navale, Y. Jiang, J. Aycock, M. Elias, D. Chang, J. Wieszorek, W. Y. Go, Axicabtagene Ciloleucel CAR T-
- 570 Cell Therapy in Refractory Large B-Cell Lymphoma. *New England Journal of Medicine*. **377**, 2531–2544
- 571 (2017).
- 572 5. N. Raje, J. Berdeja, Y. Lin, D. Siegel, S. Jagannath, D. Madduri, M. Liedtke, J. Rosenblatt, M. v. Maus, A.
- 573 Turka, L.-P. Lam, R. A. Morgan, K. Friedman, M. Massaro, J. Wang, G. Russotti, Z. Yang, T. Campbell, K.
- 574 Hege, F. Petrocca, M. T. Quigley, N. Munshi, J. N. Kochenderfer, Anti-BCMA CAR T-Cell Therapy bb2121
- 575 in Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*. **380**, 1726–1737 (2019).
- 576 6. N. C. Munshi, L. D. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Y. Lin, D. Siegel, A.
- 577 Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A.
- 578 Rambaldi, D. Reece, F. Petrocca, M. Massaro, J. N. Connarn, S. Kaiser, P. Patel, L. Huang, T. B. Campbell,
- 579 K. Hege, J. San-Miguel, Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *The New*
- 580 *England journal of medicine*. **384**, 705–716 (2021).
- 581 7. J. G. Berdeja, D. Madduri, S. Z. Usmani, A. Jakubowiak, M. Agha, A. D. Cohen, A. K. Stewart, P. Hari, M.
- 582 Htut, A. Lesokhin, A. Deol, N. C. Munshi, E. O'Donnell, D. Avigan, I. Singh, E. Zudaire, T. M. Yeh, A. J.
- 583 Allred, Y. Olyslager, A. Banerjee, C. C. Jackson, J. D. Goldberg, J. M. Schecter, W. Deraedt, S. H. Zhuang,
- 584 J. Infante, D. Geng, X. Wu, M. J. Carrasco-Alfonso, M. Akram, F. Hossain, S. Rizvi, F. Fan, Y. Lin, T.
- 585 Martin, S. Jagannath, Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen
- 586 receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase
- 587 1b/2 open-label study. *The Lancet* (2021), doi:10.1016/S0140-6736(21)00933-8.
- 588 8. R. G. Majzner, S. P. Rietberg, E. Sotillo, R. Dong, V. T. Vachharajani, L. Labanieh, J. H. Myklebust, M.
- 589 Kadapakkam, E. W. Weber, A. M. Tousley, R. M. Richards, S. Heitzeneder, S. M. Nguyen, V. Wiebking, J.
- 590 Theruvath, R. C. Lynn, P. Xu, A. R. Dunn, R. D. Vale, C. L. Mackall, Tuning the antigen density
- 591 requirement for car T-cell activity. *Cancer Discovery*. **10**, 702–723 (2020).
- 592 9. F. L. Locke, J. M. Rossi, S. S. Neelapu, C. A. Jacobson, D. B. Miklos, A. Ghobadi, O. O. Oluwole, P. M.
- 593 Reagan, L. J. Lekakis, Y. Lin, M. Sherman, M. Better, W. Y. Go, J. S. Wieszorek, A. Xue, A. Bot, Tumor
- 594 burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell
- 595 lymphoma. *Blood Advances*. **4**, 4898–4911 (2020).
- 596 10. O. U. Kawalekar, R. S. O'Connor, J. A. Fraietta, L. Guo, S. E. McGettigan, A. D. Posey, P. R. Patel, S.
- 597 Guedan, J. Scholler, B. Keith, N. Snyder, I. Blair, M. C. Milone, C. H. June, Distinct Signaling of
- 598 Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
- 599 *Immunity*. **44**, 380–390 (2016).
- 600 11. S. Guedan, A. D. Posey, C. Shaw, A. Wing, T. Da, P. R. Patel, S. E. McGettigan, V. Casado-Medrano, O. U.
- 601 Kawalekar, M. Uribe-Herranz, D. Song, J. J. Melenhorst, S. F. Lacey, J. Scholler, B. Keith, R. M. Young, C.
- 602 H. June, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI insight*. **3** (2018),
- 603 doi:10.1172/jci.insight.96976.
- 604 12. L. Alabanza, M. Pegues, C. Geldres, V. Shi, J. J. W. Wiltzius, S. A. Sievers, S. Yang, J. N. Kochenderfer,
- 605 Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by
- 606 Hinge and Transmembrane Domains. *Molecular Therapy*. **25**, 2452–2465 (2017).
- 607 13. A. L. Garfall, E. K. Dancy, A. D. Cohen, W. T. Hwang, J. A. Fraietta, M. M. Davis, B. L. Levine, D. L.
- 608 Siegel, E. A. Stadtmauer, D. T. Vogl, A. Waxman, A. P. Rapoport, M. C. Milone, C. H. June, J. J.
- 609 Melenhorst, T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed
- 610 multiple myeloma. *Blood Advances*. **3**, 2812–2815 (2019).

- 611 14. J. Rossi, P. Paczkowski, Y. W. Shen, K. Morse, B. Flynn, A. Kaiser, C. Ng, K. Gallatin, T. Cain, R. Fan, S.  
612 Mackay, J. R. Heath, S. A. Rosenberg, J. N. Kochenderfer, J. Zhou, A. Bot, Preinfusion polyfunctional anti-  
613 CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. *Blood*. **132**, 804–814  
614 (2018).
- 615 15. C. J. Turtle, L. A. Hanafi, C. Berger, M. Hudecek, B. Pender, E. Robinson, R. Hawkins, C. Chaney, S.  
616 Cherian, X. Chen, L. Soma, B. Wood, D. Li, S. Heimfeld, S. R. Riddell, D. G. Maloney, Immunotherapy of  
617 non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-  
618 modified T cells. *Science Translational Medicine*. **8** (2016),  
619 doi:10.1097/CCM.0b013e31823da96d.Hydrogen.
- 620 16. D. Sommermeyer, M. Hudecek, P. L. Kosasih, T. Gogishvili, D. G. Maloney, C. J. Turtle, S. R. Riddell,  
621 *Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior*  
622 *antitumor reactivity in vivo* (Nature Publishing Group, 2016; <http://dx.doi.org/10.1038/leu.2015.247>), vol.  
623 30.
- 624 17. A. H. Long, W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J. Walker,  
625 M. E. Kohler, V. R. Venkateshwara, R. N. Kaplan, G. H. Patterson, T. J. Fry, R. J. Orentas, C. L. Mackall, 4-  
626 1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.  
627 *Nature Medicine* (2015), doi:10.1038/nm.3838.
- 628 18. M. J. Frigault, J. Lee, M. C. Basil, C. Carpenito, S. Motohashi, J. Scholler, O. U. Kawalekar, S. Guedan, S.  
629 E. McGettigan, A. D. Posey, S. Ang, L. J. N. Cooper, J. M. Platt, F. B. Johnson, C. M. Paulos, Y. Zhao, M.  
630 Kalos, M. C. Milone, C. H. June, Identification of chimeric antigen receptors that mediate constitutive or  
631 inducible proliferation of T cells. *Cancer Immunology Research*. **3**, 356–367 (2015).
- 632 19. S. Sukumaran, N. Watanabe, P. Bajgain, K. Raja, S. Mohammed, W. E. Fisher, M. K. Brenner, A. M. Leen,  
633 J. F. Vera, Enhancing the potency and specificity of engineered T cells for cancer treatment. *Cancer*  
634 *Discovery*. **8**, 972–987 (2018).
- 635 20. D. Gomes-Silva, M. Mukherjee, M. Srinivasan, G. Krenciute, O. Dakhova, Y. Zheng, J. M. S. Cabral, C. M.  
636 Rooney, J. S. Orange, M. K. Brenner, M. Mamonkin, Tonic 4-1BB Costimulation in Chimeric Antigen  
637 Receptors Impedes T Cell Survival and Is Vector-Dependent. *Cell Reports* (2017),  
638 doi:10.1016/j.celrep.2017.09.015.
- 639 21. J. Eyquem, J. Mansilla-Soto, T. Giavridis, S. J. C. van der Stegen, M. Hamieh, K. M. Cunanan, A. Odak, M.  
640 Gönen, M. Sadelain, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.  
641 *Nature*. **543**, 113–117 (2017).
- 642 22. M. Tristán-Manzano, N. Maldonado-Pérez, P. Justicia-Lirio, P. Muñoz, M. Cortijo-Gutiérrez, K. Pavlovic,  
643 R. Jiménez-Moreno, S. Nogueras, Md. Carmona, S. Sánchez-Hernández, A. Aguilar-González, M. Castella,  
644 M. Juan, C. Marañón, K. Benabdellah, C. Herrera, F. Martin, *medRxiv*, in press (available at  
645 <http://medrxiv.org/content/early/2021/03/20/2021.03.17.21253300.abstract>).
- 646 23. J. Y. Ho, L. Wang, Y. Liu, M. Ba, J. Yang, X. Zhang, D. Chen, P. Lu, J. Li, Promoter usage regulating the  
647 surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. *Molecular Therapy -*  
648 *Methods and Clinical Development*. **21**, 237–246 (2021).
- 649 24. A. J. Walker, R. G. Majzner, L. Zhang, K. Wanhainen, A. H. Long, S. M. Nguyen, P. Lopomo, M. Vigny, T.  
650 J. Fry, R. J. Orentas, C. L. Mackall, Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric  
651 Antigen Receptor Targeting Anaplastic Lymphoma Kinase. *Molecular Therapy*. **25**, 2189–2201 (2017).
- 652 25. J. A. Fraietta, S. F. Lacey, E. J. Orlando, I. Pruteanu-Malinici, M. Gohil, S. Lundh, A. C. Boesteanu, Y.  
653 Wang, R. S. O'connor, W. T. Hwang, E. Pequignot, D. E. Ambrose, C. Zhang, N. Wilcox, F. Bedoya, C.  
654 Dorfmeier, F. Chen, L. Tian, H. Parakandi, M. Gupta, R. M. Young, F. B. Johnson, I. Kulikovskaya, L. Liu,  
655 J. Xu, S. H. Kassim, M. M. Davis, B. L. Levine, N. v. Frey, D. L. Siegel, A. C. Huang, E. J. Wherry, H.  
656 Bitter, J. L. Brogdon, D. L. Porter, C. H. June, J. J. Melenhorst, Determinants of response and resistance to  
657 CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*.  
658 **24**, 563–571 (2018).
- 659 26. Q. Deng, G. Han, N. Puebla-Osorio, M. C. J. Ma, P. Strati, B. Chasen, E. Dai, M. Dang, N. Jain, H. Yang, Y.  
660 Wang, S. Zhang, R. Wang, R. Chen, J. Showell, S. Ghosh, S. Patchva, Q. Zhang, R. Sun, F. Hagemester, L.  
661 Fayad, F. Samaniego, H. C. Lee, L. J. Nastoupil, N. Fowler, R. Eric Davis, J. Westin, S. S. Neelapu, L.  
662 Wang, M. R. Green, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and  
663 toxicity in patients with large B cell lymphomas. *Nature Medicine* (2020), doi:10.1038/s41591-020-1061-7.
- 664 27. A. Sheih, V. Voillet, L. A. Hanafi, H. A. DeBerg, M. Yajima, R. Hawkins, V. Gersuk, S. R. Riddell, D. G.  
665 Maloney, M. E. Wohlfahrt, D. Pande, M. R. Enstrom, H. P. Kiem, J. E. Adair, R. Gottardo, P. S. Linsley, C.  
666 J. Turtle, Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing  
667 CD19 CAR-T immunotherapy. *Nature Communications*. **11** (2020), doi:10.1038/s41467-019-13880-1.
- 668 28. A. C. Boroughs, R. C. Larson, N. D. Marjanovic, K. Gosik, A. P. Castano, C. B. M. Porter, S. J. Lorrey, O.  
669 Ashenberg, L. Jerby, M. Hofree, G. Smith-Rosario, R. Morris, J. Gould, L. S. Riley, T. R. Berger, S. J.  
670 Riesenfeld, O. Rozenblatt-Rosen, B. D. Choi, A. Regev, M. v. Maus, A Distinct Transcriptional Program in

- 671 Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. *Molecular Therapy*. **28**  
672 (2020), doi:10.1016/j.ymthe.2020.07.023.
- 673 29. G. M. Chen, C. Chen, R. K. Das, P. Gao, C. H. Chen, S. Bandyopadhyay, Y. Y. Ding, Y. Uzun, W. Yu, Q.  
674 Zhu, R. M. Myers, S. A. Grupp, D. M. Barrett, K. Tan, Integrative bulk and single-cell profiling of  
675 premanufacture t-cell populations reveals factors mediating long-term persistence of car t-cell therapy.  
676 *Cancer Discovery*. **11**, 2186–2199 (2021).
- 677 30. Q. Zhang, H. Hu, S. Y. Chen, C. J. Liu, F. F. Hu, J. Yu, Y. Wu, A. Y. Guo, Transcriptome and Regulatory  
678 Network Analyses of CD19-CAR-T Immunotherapy for B-ALL. *Genomics, Proteomics and Bioinformatics*.  
679 **17**, 190–200 (2019).
- 680 31. S. Roskopf, J. Leitner, W. Paster, L. T. Morton, R. S. Hagedoorn, P. Steinberger, M. H. M. Heemskerk, A  
681 Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies.  
682 *Oncotarget*. **9**, 17608–17619 (2018).
- 683 32. J. Feucht, J. Sun, J. Eyquem, Y. J. Ho, Z. Zhao, J. Leibold, A. Dobrin, A. Cabriolu, M. Hamieh, M. Sadelain,  
684 Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nature*  
685 *Medicine*. **25**, 82–88 (2019).
- 686 33. C. U. Blank, W. N. Haining, W. Held, P. G. Hogan, A. Kallies, E. Lugli, R. C. Lynn, M. Philip, A. Rao, N.  
687 P. Restifo, A. Schietinger, T. N. Schumacher, P. L. Schwartzberg, A. H. Sharpe, D. E. Speiser, E. J. Wherry,  
688 B. A. Youngblood, D. Zehn, Defining ‘T cell exhaustion.’ *Nature Reviews Immunology*. **19**, 665–674 (2019).
- 689 34. J. Peng, G. Serrano, I. M. Traniello, M. E. Calleja-Cervantes, U. v Chembazhi, S. Bangru, T. Ezponda, J.  
690 Roberto Rodriguez-Madoz, A. Kalsotra, F. Prosper, I. Ochoa, M. Hernaez, A single-cell gene regulatory  
691 network inference method for identifying complex regulatory dynamics across cell phenotypes. *Bioarxiv*, 1–  
692 31 (2021).
- 693 35. I. C. Ho, T. S. Tai, S. Y. Pai, GATA3 and the T-cell lineage: Essential functions before and after T-helper-2-  
694 cell differentiation. *Nature Reviews Immunology*. **9**, 125–135 (2009).
- 695 36. D. Wang, H. Diao, A. J. Getzler, W. Rogal, M. A. Frederick, J. Milner, B. Yu, S. Crotty, A. W. Goldrath, M.  
696 E. Pipkin, The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory  
697 Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. *Immunity*. **48**, 659-674.e6 (2018).
- 698 37. G. Gaud, R. Lesourne, P. E. Love, Regulatory mechanisms in T cell receptor signalling. *Nature Reviews*  
699 *Immunology*. **18**, 485–497 (2018).
- 700 38. A. M. Siegel, J. Heimall, A. F. Freeman, A. P. Hsu, E. Brittain, J. M. Brenchley, D. C. Douek, G. H. Fahle, J.  
701 I. Cohen, S. M. Holland, J. D. Milner, A critical role for STAT3 transcription factor signaling in the  
702 development and maintenance of human T cell memory. *Immunity*. **35**, 806–818 (2011).
- 703 39. K. Masuda, B. Ripley, K. K. Nyati, P. K. Dubey, M. M. U. Zaman, H. Hanieh, M. Higa, K. Yamashita, D.  
704 M. Standley, T. Mashima, M. Katahira, T. Okamoto, Y. Matsuura, O. Takeuchi, T. Kishimoto, Arid5a  
705 regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. *Journal of Experimental*  
706 *Medicine*. **213**, 605–619 (2016).
- 707 40. S. S. Hwang, J. Lim, Z. Yu, P. Kong, E. Sefik, H. Xu, C. C. D. Harman, L. K. Kim, G. R. Lee, H.-B. Li, R.  
708 A. Flavell, mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. *Science* (2020),  
709 doi:10.1126/science.aax0194.
- 710 41. J. Villard, M. Peretti, K. Masternak, E. Barras, G. Caretti, R. Mantovani, W. Reith, A Functionally Essential  
711 Domain of RFX5 Mediates Activation of Major Histocompatibility Complex Class II Promoters by  
712 Promoting Cooperative Binding between RFX and NF- $\kappa$ B. *Molecular and Cellular Biology* (2000),  
713 doi:10.1128/mcb.20.10.3364-3376.2000.
- 714 42. P. Rousseau, K. Masternak, M. Krawczyk, W. Reith, J. Dausset, E. D. Carosella, P. Moreau, In vivo, RFX5  
715 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class  
716 I protein expression in a cell type-dependent manner. *Immunology* (2004), doi:10.1111/j.1365-  
717 2567.2004.01783.x.
- 718 43. J. Chen, I. F. López-Moyado, H. Seo, C. W. J. Lio, L. J. Hempleman, T. Sekiya, A. Yoshimura, J. P. Scott-  
719 Browne, A. Rao, NR4A transcription factors limit CAR T cell function in solid tumours. *Nature*. **567**, 530–  
720 534 (2019).
- 721 44. X. Liu, Y. Wang, H. Lu, J. Li, X. Yan, M. Xiao, J. Hao, A. Alekseev, H. Khong, T. Chen, R. Huang, J. Wu,  
722 Q. Zhao, Q. Wu, S. Xu, X. Wang, W. Jin, S. Yu, Y. Wang, L. Wei, A. Wang, B. Zhong, L. Ni, X. Liu, R.  
723 Nuriyeva, L. Ye, Q. Tian, X. W. Bian, C. Dong, Genome-wide analysis identifies NR4A1 as a key mediator  
724 of T cell dysfunction. *Nature*. **567**, 525–529 (2019).
- 725 45. M. Giordano, C. Henin, J. Maurizio, C. Imbratta, P. Bourdely, M. Buferne, L. Baitsch, L. Vanhille, M. H.  
726 Sieweke, D. E. Speiser, N. Auphan-Anezin, A. Schmitt-Verhulst, G. Verdeil, Molecular profiling of CD 8 T  
727 cells in autochthonous melanoma identifies Maf as driver of exhaustion . *The EMBO Journal*. **34**, 2042–2058  
728 (2015).
- 729 46. T. L. Stephen, K. K. Payne, R. A. Chaurio, M. J. Allegranza, H. Zhu, J. Perez-Sanz, A. Perales-Puchalt, J. M.  
730 Nguyen, A. E. Vara-Ailor, E. B. Eruslanov, M. E. Borowsky, R. Zhang, T. M. Laufer, J. R. Conejo-Garcia,



- 731 SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. *Immunity* (2017),  
732 doi:10.1016/j.immuni.2016.12.015.
- 733 47. R. G. Majzner, C. L. Mackall, Tumor antigen escape from car t-cell therapy. *Cancer Discovery* (2018), ,  
734 doi:10.1158/2159-8290.CD-18-0442.
- 735 48. N. W. C. J. van de Donk, M. Themeli, S. Z. Usmani, Determinants of response and mechanisms of resistance  
736 of CAR T-cell therapy in multiple myeloma. **2**, 302–318 (2021).
- 737 49. J. Jayaraman, M. P. Mellody, A. J. Hou, R. P. Desai, A. W. Fung, A. H. T. Pham, Y. Y. Chen, W. Zhao,  
738 CAR-T design: Elements and their synergistic function. *EBioMedicine*. **58** (2020),  
739 doi:10.1016/j.ebiom.2020.102931.
- 740 50. A. Ajina, J. Maher, Strategies to address chimeric antigen receptor tonic signaling. *Molecular Cancer*  
741 *Therapeutics* (2018), , doi:10.1158/1535-7163.MCT-17-1097.
- 742 51. Y. D. Muller, D. P. Nguyen, L. M. R. Ferreira, P. Ho, C. Raffin, R. V. B. Valencia, Z. Congrave-Wilson, T.  
743 L. Roth, J. Eyquem, F. van Gool, A. Marson, L. Perez, J. A. Wells, J. A. Bluestone, Q. Tang, The CD28-  
744 Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. *Frontiers in*  
745 *Immunology* (2021), doi:10.3389/fimmu.2021.639818.
- 746 52. S. M. A. H. Rad, A. Poudel, G. M. Y. Tan, A. D. McLellan, Promoter choice: Who should drive the CAR in  
747 T cells? *PLoS ONE*. **15**, 1–18 (2020).
- 748 53. S. Guedan, A. Madar, V. Casado-Medrano, C. Shaw, A. Wing, F. Liu, R. M. Young, C. H. June, A. D.  
749 Posey, Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor  
750 durability. *Journal of Clinical Investigation*. **130**, 3087–3097 (2020).
- 751 54. J. Eyquem, J. Mansilla-Soto, T. Giavridis, S. J. C. Van Der Stegen, M. Hamieh, K. M. Cunanan, A. Odak,  
752 M. Gönen, M. Sadelain, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.  
753 *Nature*. **543**, 113–117 (2017).
- 754 55. R. Greenman, Y. Pizem, M. Haus-Cohen, A. Goor, G. Horev, G. Denkberg, K. Sinik, Y. Elbaz, V. Bronner,  
755 A. G. Levin, G. Horn, S. Shen-Orr, Y. Reiter, Shaping functional avidity of CAR T Cells: Affinity, avidity,  
756 and antigen density that regulate response. *Molecular Cancer Therapeutics*. **20**, 872–884 (2021).
- 757 56. B. Salzer, C. M. Schueller, C. U. Zajc, T. Peters, M. A. Schoeber, B. Kovacic, M. C. Buri, E. Lobner, O.  
758 Dushek, J. B. Huppa, C. Obinger, E. M. Putz, W. Holter, M. W. Traxlmayr, M. Lehner, Engineering  
759 AvidCARs for combinatorial antigen recognition and reversible control of CAR function. *Nature*  
760 *Communications*. **11**, 1–16 (2020).
- 761 57. C. Fernández de Larrea, M. Staehr, A. v. Lopez, K. Y. Ng, Y. Chen, W. D. Godfrey, T. J. Purdon, V.  
762 Ponomarev, H.-G. Wendel, R. J. Brentjens, E. L. Smith, Defining an Optimal Dual-Targeted CAR T-cell  
763 Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven  
764 Relapse in Multiple Myeloma. *Blood Cancer Discovery*. **1**, 146–154 (2020).
- 765 58. J. G. Berdeja, D. Madduri, S. Z. Usmani, I. Singh, E. Zudaire, T.-M. Yeh, A. J. Allred, Y. Olyslager, A.  
766 Banerjee, J. D. Goldberg, J. Schechter, D. Geng, X. Wu, M. Carrasco-Alfonso, S. Rizvi, F. (Xiaohu) Fan, A.  
767 J. Jakubowiak, S. Jagannath, Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell  
768 maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. *Journal*  
769 *of Clinical Oncology* (2020), doi:10.1200/jco.2020.38.15\_suppl.8505.
- 770 59. D. A. Jaitin, E. Kenigsberg, H. Keren-Shaul, N. Elefant, F. Paul, I. Zaretsky, A. Mildner, N. Cohen, S. Jung,  
771 A. Tanay, I. Amit, Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell  
772 types. *Science* (2014), doi:10.1126/science.1247651.
- 773 60. Y. Lavin, S. Kobayashi, A. Leader, E. ad D. Amir, N. Elefant, C. Bigenwald, R. Remark, R. Sweeney, C. D.  
774 Becker, J. H. Levine, K. Meinhof, A. Chow, S. Kim-Shulze, A. Wolf, C. Medaglia, H. Li, J. A. Rytlewski, R.  
775 O. Emerson, A. Solovyov, B. D. Greenbaum, C. Sanders, M. Vignali, M. B. Beasley, R. Flores, S. Gnjjatic,  
776 D. Pe'er, A. Rahman, I. Amit, M. Merad, Innate Immune Landscape in Early Lung Adenocarcinoma by  
777 Paired Single-Cell Analyses. *Cell* (2017), doi:10.1016/j.cell.2017.04.014.
- 778 61. M. R. Corces, J. D. Buenrostro, B. Wu, P. G. Greenside, S. M. Chan, J. L. Koenig, M. P. Snyder, J. K.  
779 Pritchard, A. Kundaje, W. J. Greenleaf, R. Majeti, H. Y. Chang, Lineage-specific and single-cell chromatin  
780 accessibility charts human hematopoiesis and leukemia evolution. *Nature Genetics* (2016),  
781 doi:10.1038/ng.3646.
- 782 62. B. G. M. Durie, J. L. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie, K. Anderson, M. Gertz, M.  
783 Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksac, J. Crowley, A. Belch, M.  
784 Boccadaro, M. Cavo, I. Turesson, D. Joshua, D. Vesole, R. Kyle, G. Tricot, R. Alexanian, M. Attal, G.  
785 Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, S. v. Rajkumar, G. Morgan, International uniform  
786 response criteria for multiple myeloma. *Leukemia*. **20**, 1467–1473 (2006).
- 787  
788

## 789 **Acknowledgments**

790 We thank the members of Hematology and Cell Therapy Department of the Clinica Universidad  
791 de Navarra for input throughout the course of the project and all the patients as well as families  
792 who made this study possible. We particularly acknowledge the patients for their participation in  
793 the Clinical trial CARTBCMA-HCB-01 (NCT04309981) and the Biobank of the University of  
794 Navarra for its collaboration.

795

## 796 **Funding**

797 This study was supported by the Instituto de Salud Carlos III co-financed by European Regional  
798 Development Fund-FEDER “A way to make Europe” (PI19/00669, ICI19/00025 and  
799 ICI19/00069). Red de Terapia Celular TERCEL (RD16/0011/0005). Redes de Investigación  
800 Cooperativa Orientada a Resultados en Salud RICORS (RD21/0017/0009 and RD21/0017/0019).  
801 Centro de Investigación Biomédica en Red de Cáncer CIBERONC (CB16/12/00369 and  
802 CB16/12/00489). Ministerio de Ciencia e Innovación co-financed by European Regional  
803 Development Fund-FEDER “A way to make Europe” (RTC-2017-6578-1 and PID2019-  
804 108989RB-I00.). European Commission (H2020-JTI-IMI2-2019-18: Contract 945393; SC1-PM-  
805 08-2017: Contract 754658; and H2020-MSCA-IF-2019: Grant Agreement 898356). Gobierno de  
806 Navarra (AGATA: 0011-1411-2020-000011 and 0011-1411-2020-000010; DESCARTHeS: 0011-  
807 1411-2019-000079 and 0011-1411-2019-000072; alloCART-LMA: PC011-012). Fundacion La  
808 Caixa (CP042702). Asociacion Española Contra el Cáncer-AECC (LABAE21971FERN). Paula  
809 and Rodger Riney Foundation. Paula Rodriguez-Marquez was supported by FPU grant  
810 (FPU19/06160) from Ministerio de Universidades.

811

## 812 **Author contributions**

813 P.R-M., M.E.C-C., G.S, M.H., J.R.R-M., and F.P. designed the experiments. P.R-M., M.E.C-C.,  
814 G.S, A.M-M. and C.C. conducted the experiments. P.R-M., M.E.C-C., G.S, A.O-C., M.H. and  
815 J.R.R-M. performed the data analysis. M.L.P-B., P.R-O., A.A. and J.S-M. provided clinical advice.  
816 A.O-C., M.E-R., C.C., M.C.V., M.R. M.P., M.J., A.U., C.F-L. and B.P. provided clinical samples  
817 and data. T.L., J.J.L., B.P., M.H., J.R.R-M., and F.P discussed the study design and the results.  
818 P.S-M., A.V-Z., S.R-D., R.M-T. and D.A. provided technical assistance. M.H., J.R.R-M., and F.P.  
819 were responsible for research supervision, coordination, and strategy. P.R-M. and J.R.R-M. drafted  
820 the manuscript. J.J.L., J.S-M., C.F-L., M.H., J.R.R-M., and F.P. reviewed and edited the  
821 manuscript. All authors reviewed and approved the final version of the manuscript.

822

## 823 **Competing interests**

824 Authors declare that they have no competing interests.

825

## 826 **Data and materials availability**

827 All data needed to evaluate the conclusions in the paper are present in the paper and/or the  
828 Supplementary Materials. The RNA-seq, ATAC-seq, and scRNA-seq data generated in this study  
829 have been deposited in the GEO database (GEO#) and will be available upon publication.  
830 Additional data related to this paper may be requested from the authors.

831

## 832 Figures and Tables

833

834 **Fig. 1. CAR<sup>High</sup> T cells present increased *in vitro* antitumoral efficacy and exhausted**  
835 **phenotype.** An *in vitro* functional and phenotypic characterization was performed on CAR T cells  
836 targeting BCMA presenting different densities of the CAR molecule. **(A)** Schematic representation  
837 of the procedure. CAR T cells were sorted into CAR<sup>High</sup> and CAR<sup>Low</sup> subpopulations via BFP  
838 expression. Analyses were performed at basal state or after stimulation with tumor cells expressing  
839 BCMA. **(B)** Quantification of the cytotoxic activity of CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells against  
840 ARP1-GFPLuc at different E:T ratio. The percentage of specific lysis (average of three technical  
841 replicates) for each CAR T cell production (n=6) is depicted. **(C)** Quantification of IFN $\gamma$ , IL-2 and  
842 TNF $\alpha$  levels in supernatants from cytotoxic assays (ratio 0.5:1) measured by ELISA. The cytokine  
843 concentration (pg/ml; average of three technical replicates) for each CAR T cell production (n=6)  
844 is depicted. **(D)** Cytotoxic activity of ARI-0002h CAR T products from CARTBCMA-HCB-01  
845 clinical trial, according to their enrichment in CAR<sup>High</sup> T cells. **(E)** Analysis of the phenotype of  
846 CAR<sup>High</sup> and CAR<sup>Low</sup> T cell populations before (basal n=10) and after stimulation (Stim n=5) with  
847 ARP1-GFPLuc tumor cells. Mean  $\pm$  SEM of each T cell subpopulation within CAR<sup>High</sup> T and  
848 CAR<sup>Low</sup> T cells from is depicted. T<sub>N</sub>: naïve; T<sub>SCM</sub>: stem central memory; T<sub>CM</sub>: central memory;  
849 T<sub>EM</sub>: effector memory; T<sub>E</sub>: effector. Analysis of the expression of HLA-DR **(F)**, CD137 **(G)** and a  
850 combination of >2 exhaustion markers (LAG3, TIM3 and/or PD1) **(H)**, in CAR<sup>High</sup> T and CAR<sup>Low</sup>  
851 T cells before (basal n=10) and after stimulation (Stim n=5) with ARP1-GFPLuc tumor cells.  
852 Wilcoxon test for paired samples (B and C), Mann-Whitney test (D), and 2-way ANOVA with  
853 Sidak's multiple comparison(F-H). \*p<0.05; \*\*p<0.01; \*\*\*p<0.001.

854

855 **Fig. 2. *In vivo* antitumoral efficacy of CAR T cells with different CAR densities.** **(A)** Schematic  
856 representation of the experimental procedure. NGS mice were injected intravenously (i.v.) on day  
857 0 with 1x10<sup>6</sup> ARP1GFPLuc cells/animal. After 6 days 0.5x10<sup>6</sup> CAR<sup>High</sup> T or CAR<sup>Low</sup> T cells were  
858 injected i.v. Bioluminescence analysis (BLI) was performed on days 14, 35 and 49. Animal survival  
859 was monitored until the end of the experiment (day 67). On day 28 a subset of animals was  
860 sacrificed to analyze the presence of tumor and CAR T cells. **(B)** BLI images at the indicated days  
861 of control mice (n=4) or treated with CAR<sup>High</sup> T cells (n=6) or CAR<sup>Low</sup> T cells (n=6). **(C)**  
862 Quantification of BLI (ph/s/cm<sup>2</sup>/sr) as a measurement of tumor growth. **(D)** Quantification of the  
863 tumor cells present in the bone marrow (BM) of control mice (n=3) or treated with CAR<sup>High</sup> T cells  
864 (n=6) or CAR<sup>Low</sup> T cells (n=6) at day 28 after CAR T cell administration. **(E)** Survival of control  
865 mice (n=4) or treated with CAR<sup>High</sup> T cells (n=6) or CAR<sup>Low</sup> T cells (n=6). **(F)** Quantification of  
866 the CAR T cells present in the BM of animals treated with CAR<sup>High</sup> T cells (n=6) or CAR<sup>Low</sup> T  
867 cells (n=6) at day 28 after CAR T cell administration. Kruskal-Wallis test (D), Mantel-Cox (Long-  
868 Rank) test (E), and Mann-Whitney test (E). ns: not significant; \*p<0.05.

869

870 **Fig. 3. Transcriptomic profile and chromatin landscape of CD8<sup>+</sup> CAR<sup>High</sup> T cells.** The  
871 transcriptomic and epigenetic landscape of sorted CD8<sup>+</sup> and CD4<sup>+</sup> (see Fig. S6) CAR<sup>High</sup> and  
872 CAR<sup>Low</sup> T cells (n=6) were profiled using high-throughput RNA sequencing (RNA-seq) and assay  
873 for transposase-accessible chromatin (ATAC-seq). **(A)** RNA-seq and ATAC-seq principal  
874 components (PC) analysis, corrected by patient heterogeneity, of sorted CD8<sup>+</sup> CAR T cell subsets.  
875 Percentage of variance explained by PC1 and PC2 are depicted. **(B)** Heatmap of differentially  
876 expressed genes (DEGs) between CD8<sup>+</sup> CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells associated to genes  
877 involved in tonic signaling and T cell activation. **(C)** Quantification of HLA-DR, CD74, TNFRSF4  
878 (OX40) and TNFRSF9 (4-1BB) gene expression in CD8<sup>+</sup> CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells. **(D)**  
879 UCSC genome browser tracks of CTLA-4, HLA-DRA, CIITA and TNFRSF9 showing differential

880 peaks from ATAC-seq analysis between CD8<sup>+</sup> CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells. Wilcoxon test for  
881 paired samples (C). \*p<0.05.

882

883 **Fig. 4. Characterization of CAR T cells at single cell level.** CAR<sup>+</sup> (BFP<sup>+</sup>) cells from three  
884 independent CAR T cell productions were assayed by single-cell RNA sequencing. (A) An  
885 overview of the 28,117 cells that passed QC and filtering for subsequent analyses in this study.  
886 UMAP plot showing the 15 clusters that were analyzed. (B) Heatmap showing signature genes of  
887 each cluster and putative assignments to cell types according to canonical marker genes. (C)  
888 UMAP plot overlaid with mRNA expression of T cell markers (CD4 and CD8A), memory markers  
889 (TCF7 and CCR7), activation markers (HLA-DRA and GATA3), effector enzymes (GZMA and  
890 PRF1) and exhaustion markers (LAG3 and TIGIT).

891

892 **Fig. 5. Single-cell sequencing reveals specific distribution of CAR<sup>High</sup> T cells.** Annotation and  
893 further analysis of CAR<sup>High</sup> T in the single cell data was performed by applying the gene signatures,  
894 developed in this work, associated to both CD4<sup>+</sup> and CD8<sup>+</sup> CAR<sup>High</sup> T cells, that showed higher  
895 correlation with the CAR protein level than that yielded by the CAR gene expression. (A) UMAP  
896 plot showing CAR<sup>High</sup> T cell distribution across analyzed cells. (B) Quantification of the percentage  
897 of CAR<sup>High</sup> T cell along the different clusters. In accordance with phenotypic results, CAR<sup>High</sup> T  
898 cells are mainly localized within activated CD4<sup>+</sup> cells (cluster 6 and 17) and pre-exhausted CD8<sup>+</sup>  
899 T cells (cluster 9). (C) UMAP plots overlaid with the score of activation and tonic signaling  
900 signatures, showing their distribution across cells. CAR<sup>High</sup> T cells were enriched in the score for  
901 both signatures. (D) Quantification of the signature score in CAR<sup>High</sup> T cells from clusters 6 (CD4<sup>+</sup>  
902 activated), 8 (CD8<sup>+</sup> cytotoxic) and 9 (CD8<sup>+</sup> pre-exhausted), in comparison with the rest of the cells,  
903 for both activation and tonic signaling signatures. CAR<sup>High</sup> T cells presented a significant increase  
904 for both signatures in almost all three clusters analyzed. Wilcoxon test (D). \*\*\*p<0.001.

905

906 **Fig. 6. CAR density is associated with differential activation of regulatory networks.**  
907 Dynamics in Gene Regulatory Networks (GRN) of CAR<sup>High</sup> T cells were analyzed by SimiC, a  
908 novel GRN inference algorithm for scRNA-seq data that imposes a similarity constraint when  
909 jointly inferring the GRNs for each specific cell state. Histograms showing the activity score during  
910 CD8<sup>+</sup> T cell differentiation in CAR<sup>High</sup> T cells versus the rest of the cells (A), and the inferred gene  
911 network (B), of regulons RFX5, NR4A1, MAF and SATB1. Regulon activity of RFX5, a member  
912 of the RFX family that interacts with HLA class II genes and promotes their transcription, and  
913 NR4A1 and MAF, that have been described as drivers of T cell exhaustion, was already high in  
914 CAR<sup>High</sup> T cells, independently of the phenotype, meanwhile in the rest of the cells, their activity  
915 progressively increased, from CD8<sup>+</sup> memory (cluster 3), to CD8<sup>+</sup> cytotoxic (cluster 8) and finally  
916 to CD8<sup>+</sup> pre-exhausted (cluster 9) phenotypes. In contrast activity of SATB1 regulon, related to  
917 PD1 inhibition, was reduced in CAR<sup>High</sup> T cells.

918

919 **Fig. 7. Increased CAR levels negatively impact clinical response of CAR T therapies.** To  
920 evaluate the impact of increased CAR density on the clinical response, we quantify the presence of  
921 CAR<sup>High</sup> T cells in the infusion products of several clinical trials. (A) The gene signatures  
922 developed in this works, associated to CD4<sup>+</sup> and CD8<sup>+</sup> CAR<sup>High</sup> T cells, were applied to 34 infusion  
923 products from adult CLL patients treated with CTL019. Signature score for each CAR T cell  
924 product is represented for both CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) gene signatures, in patients divided  
925 according to clinical response into CR/PRTD (Complete Response/Partial Response with  
926 Transformed Disease) and PR/NP (Partial Response/Non Response). Products from patients with



927 poor clinical response (PR/NR) presented a significant higher score of both CAR<sup>High</sup> T signatures.  
928 **(B)** Our gene signature was applied to available single cell RNA-seq dataset from 24 CAR T  
929 infusion products from adult DLBCL patients treated with axi-cel. Percentage of CD8<sup>+</sup> CAR<sup>High</sup> T  
930 present for each CAR T cell product is represented in patients divided according to clinical  
931 response as described in (A). Products from PR/NR patients were significantly enriched in CD8<sup>+</sup>  
932 CAR<sup>High</sup> T cells. **(C)** The number of CAR molecules/cell in 25 anti-BCMA CAR T infusion  
933 products from CARTBCMA-HCB-01 clinical trial was quantified by FACS. CAR<sup>High</sup> T cells were  
934 defined as these cells with >5000 molecules/cell (see methods). Percentage of CAR<sup>High</sup> T cells for  
935 each infusion product is represented in patients divided into sCR (Stringent Complete Response)  
936 and VGPR/PR (Very Good Partial Response/Partial Response) according to clinical response.  
937 Patients with sCR showed a significantly decreased number of CAR<sup>High</sup> T cells. Unpaired t tests  
938 (A-C). \*p<0.05; \*\*\*p<0.001.  
939

## 940 **Supplementary Materials**

941

942 Supplementary material for this article includes:

943

944 Extended Material and Methods

945 Fig. S1. CAR density influences CAR-mediated signaling.

946 Fig. S2. *In vitro* characterization of CAR T cells targeting BCMA.

947 Fig. S3. Characterization of CAR T cells with different CAR densities.

948 Fig. S4. Phenotypic characterization of CAR T cells with different CAR densities.

949 Fig. S5. Epigenetic characterization of CAR<sup>High</sup> T and CAR<sup>Low</sup> T cells.

950 Fig. S6. Transcriptomic profile and chromatin landscape of CD4<sup>+</sup> CAR<sup>High</sup> T cells.

951 Fig. S7. Characterization of CAR T cells at single cell level.

952 Fig. S8. Generation and characterization of gene signatures associated to CAR<sup>High</sup> T cells.

953 Fig. S9. Characterization of CAR<sup>High</sup> T cells at single cell level.

954 Fig. S10. Analysis of GRNs in cell with different CAR densities.

955 Table S1. List of differentially expressed genes in RNA-seq analysis between CAR<sup>High</sup> T  
956 and CAR<sup>Low</sup> T cells in both CD4<sup>+</sup> and CD8<sup>+</sup> cell subsets.

957 Table S2. List of differential peaks in ATAC-seq analysis between CAR<sup>High</sup> T and  
958 CAR<sup>Low</sup> T cells in both CD4<sup>+</sup> and CD8<sup>+</sup> cell subsets.

959 Table S3. List of VDJ clonotypes detected in scRNA-seq analysis of CAR T cells.

960 Table S4. List of the genes used for the generation of the signatures for CD4<sup>+</sup> and CD8<sup>+</sup>  
961 CAR<sup>High</sup> T cells.


962 Table S5. List of the antibodies used in this study.

963 Table S6. List of the primer and probe sequences used in this study.


964 Table S7. List of the genes used in the T cell activation and tonic signaling signatures.

965

# FIGURE 1




# FIGURE 2







# FIGURE 3





# FIGURE 4



## FIGURE 5



# FIGURE 6



# FIGURE 7

